| Members |
targetComponentId |
| ciprofloxacin 500 mg, depåtablett |
Ciprofloxacin only product in oral dose form |
| Ciprofloxacin hydrochloride + hydrocortisone 2.329mg/10mg suspension |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 2 milligram/1 milliliter and hydrocortisone 10 milligram/1 milliliter conventional release ear suspension (clinical drug) |
| Circumscribed scleroderma NOS |
Localised scleroderma |
| Cisapride 1mg/mL suspension |
Cisapride 1 mg/mL oral suspension |
| cisplatin 50 mg, pulver till infusionsvätska, lösning, flaska |
Product containing precisely cisplatin 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Cisplatin 50mg/vial powder for injection |
Product containing precisely cisplatin 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| citalopramhydrobromid 10 mg/5 ml, lösning |
Product containing precisely citalopram (as citalopram hydrobromide) 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
| citrat 6,5 %, ögondroppar |
Citric acid only product |
| citrat 6,5 %, ögondroppar utan konserveringsmedel |
Citric acid only product |
| citratallergi |
Allergy to citric acid (finding) |
| citronsyra 334 mg + kaliumcitrat 550 mg + natriumcitrat 500 mg, sirap |
Product containing precisely citric acid 66.8 milligram/1 milliliter and potassium citrate 110 milligram/1 milliliter and sodium citrate 100 milligram/1 milliliter conventional release oral solution (clinical drug) |
| citronsyra 640 mg + natriumcitrat 490 mg |
Product containing citric acid and sodium citrate (medicinal product) |
| citronsyramonohydrat 334 mg + kaliumcitrat 550 mg + natriumcitrat 500 mg, sirap |
Product containing precisely citric acid 66.8 milligram/1 milliliter and potassium citrate 110 milligram/1 milliliter and sodium citrate 100 milligram/1 milliliter conventional release oral solution (clinical drug) |
| citronsyramonohydrat 334 mg + kaliumcitrat 550 mg + natriumcitratdihydrat 500 mg, sirap |
Product containing precisely citric acid 66.8 milligram/1 milliliter and potassium citrate 110 milligram/1 milliliter and sodium citrate 100 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Citrobacter amalonaticus, biogroup 1 |
Citrobacter farmeri |
| Citrobacter diversus |
Citrobacter koseri |
| citrullinemi med sen debut |
Late-onset citrullinemia type I |
| Civil engineering technician (general) |
Civil engineering technician |
| kladribin 1 mg/ml, infusionskoncentrat, flaska 10 ml |
Cladribine 1 mg/mL solution for injection |
| Cladribine 1mg/mL injection |
Cladribine 1 mg/mL solution for injection |
| Cladribine 1mg/mL injection solution 10mL vial |
Cladribine 1 mg/mL solution for injection |
| musslor, livsmedel |
Clam (substance) |
| förpackning med klaritromycin 500 mg, tablett + lansoprazol 30 mg, kapsel + amoxycillin 500 mg, kapsel |
Amoxicillin 500 mg oral capsule |
| klassen Archaeobacteria |
Domain Archaea |
| Class Cestoidea - subclass cestoda |
Subclass Eucestoda (organism) |
| klassen Chloroflexi |
Class Chloroflexia (organism) |
| Class Eurotiomycetes |
Subclass Eurotiomycetidae (organism) |
| klassen Fibrobacteres |
Class Fibrobacteria |
| klassen Lentisphaerae |
Class Lentisphaeria (organism) |
| Class Microsporea |
Phylum Microsporidia (organism) |
| Class amphibia |
Class Amphibia (organism) |
| Class arachnida |
Arachnid |
| Class crustacea |
Subphylum Crustacea (organism) |
| Class diplopoda |
Class Diplopoda (organism) |
| klassisk laparoskopisk hysterektomi ad modum Semm |
Classic intrafascial supracervical hysterectomy (procedure) |
| klassisk mastcellsleukemi |
Mast cell leukemia (clinical) |
| klavikulär lambå |
Flap (substance) |
| Clavulanate potassium + ticarcillin disodium gm/gm injection |
Product containing clavulanic acid and ticarcillin (medicinal product) |
| Clavulanate potassium gm/ticarcillin disodium gm injection solution vial |
Product containing clavulanic acid and ticarcillin (medicinal product) |
| ren miljö |
Clean environment (finding) |
| rengöringsmedel för varma ytor |
Cleaning agent (substance) |
| toxisk effekt av rengöringsmedel för varma ytor |
Cleaning product causing toxic effect |
| rengöringsprodukt |
Cleaning agent (substance) |
| Cleaning of animal penis |
Cleaning of penis |
| klarcellstumör av mesonefroid typ, kategori |
Clear cell mesonephroid neoplasm |
| klarcellssarkom (förutom i njure M-89643) |
Clear cell sarcoma |
| Clemastine 1.34mg tablet |
Clemastine fumarate 1.34 mg oral tablet |
| klemastin 500 mikrogram/5 ml, elixir |
Product containing precisely clemastine fumarate 134 microgram/1 milliliter conventional release oral solution (clinical drug) |
| klemastinfumarat 0,67 mg/5 ml, sirap |
Product containing precisely clemastine fumarate 134 microgram/1 milliliter conventional release oral solution (clinical drug) |
| klemastin + fenylpropanolamin 0,5/25 mg, tablett |
Clemastine fumarate 670 microgram and phenylpropanolamine 25 mg oral tablet |
| Clemastine+phenylpropanolamine 0.5/25mg tablet |
Clemastine fumarate 670 microgram and phenylpropanolamine 25 mg oral tablet |
| Clemmys insculpta |
Glyptemys insculpta (organism) |
| klindamycin 1 %, kutant skum |
Product containing precisely clindamycin phosphate 10 milligram/1 milliliter conventional release cutaneous foam (clinical drug) |
| klindamycin 1,2 % / tretinoin 0,025 %, gel för lokalt bruk |
Clindamycin phosphate 12 mg/g and tretinoin 250 microgram/g cutaneous gel |
| klindamycin 2 %, kräm |
Product containing precisely clindamycin phosphate 20 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
| klindamycin 75 mg/ml, lösning för oralt bruk |
Clindamycin (as clindamycin hydrochloride) 75 mg/mL oral suspension |
| Clindamycin palmitate hydroc 75 mg/ 5mL suspension |
Clindamycin (as clindamycin hydrochloride) 75 mg/mL oral suspension |
| Clindamycin palmitate hydroc 75mg/5mL solution |
Clindamycin (as clindamycin hydrochloride) 75 mg/mL oral suspension |
| Clindamycin phosphate 1% solution |
Clindamycin (as clindamycin phosphate) 10 mg/mL cutaneous solution |
| klindamycinfosfat 100 mg, vagitorium |
Product containing precisely clindamycin (as clindamycin phosphate) 100 milligram/1 each conventional release vaginal pessary (clinical drug) |
| Clindamycin phosphate 10mg solution |
Clindamycin (as clindamycin phosphate) 10 mg/mL cutaneous solution |
| Clindamycin phosphate 10mg/mL solution |
Clindamycin (as clindamycin phosphate) 10 mg/mL cutaneous solution |
| Clindamycin phosphate 2% cream |
Product containing precisely clindamycin phosphate 20 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
| poäng enligt CORE-OM-skalan för global distress (clinical outcomes in routine evaluation outcome measure) |
Clinical Outcomes in Routine Evaluation Outcome Measure Global Distress total score |
| Clinical actions A - G |
Action |
| Clinical actions A-O |
Action |
| Clinical actions H - O |
Action |
| Clinical actions P - S |
Action |
| Clinical actions P-Z |
Action |
| Clinical actions T - Z |
Action |
| Clinical finding |
Clinical finding (finding) |
| klinisk handläggningsplan |
Clinical management plan |
| kliniskt stadium 0 |
0 |
| kliniskt stadium 1A |
IA |
| kliniskt stadium 1B |
IB |
| kliniskt stadium 1C |
IC |
| kliniskt stadium 1E |
IE |
| kliniskt stadium 1S |
American Joint Committee on Cancer stage IS (qualifier value) |
| kliniskt stadium 2A |
American Joint Committee on Cancer stage IIA (qualifier value) |
| kliniskt stadium 2B |
American Joint Committee on Cancer stage IIB (qualifier value) |
| kliniskt stadium 2C |
IIC |
| kliniskt stadium 2E |
IIE |
| kliniskt stadium 3A |
American Joint Committee on Cancer stage IIIA (qualifier value) |
| kliniskt stadium 3B |
American Joint Committee on Cancer stage IIIB (qualifier value) |
| kliniskt stadium 3C |
American Joint Committee on Cancer stage IIIC (qualifier value) |
| kliniskt stadium 4A |
American Joint Committee on Cancer stage IVA (qualifier value) |
| kliniskt stadium 4B |
IVB |
| kliniskt stadium 4C |
American Joint Committee on Cancer stage IVC (qualifier value) |
| Clinically relevant enzymes with no Enzyme Commission designation |
Enzyme |
| Clipping of organ NOC |
Closure by clip |
| biverkning av klomocyklinnatrium |
Adverse reaction to clomocycline |
| klonazepam 0,125 mg, oblatkapsel |
Product containing precisely clonazepam 125 microgram/1 each conventional release orodispersible tablet (clinical drug) |
| klonazepam 0,25 mg, oblatkapsel |
Clonazepam 250 microgram orodispersible tablet |
| klonazepam 0,5 mg, oblatkapsel |
Clonazepam 500 microgram orodispersible tablet |
| klonazepam 1 mg, oblatkapsel |
Clonazepam 1 mg orodispersible tablet |
| klonazepam 2 mg, oblatkapsel |
Clonazepam 2 mg orodispersible tablet |
| Clopidogrel bisulfate 75mg tablet |
Product containing precisely clopidogrel (as clopidogrel bisulfate) 75 milligram/1 each conventional release oral tablet (clinical drug) |
| Clorazepate dipotassium 7.5mg |
Product containing precisely dipotassium clorazepate 7.5 milligram/1 each conventional release oral tablet (clinical drug) |
| sluten anterior luxation av humerus |
Closed anterior dislocation of glenohumeral joint |
| Closed fracture finger metacarpal shaft |
Closed fracture of shaft of metacarpal bone |
| Closed fracture of C1-C4 level with other specified spinal cord injury |
Closed fracture of C1-C4 level with spinal cord injury (disorder) |
FHIR